References:
[1]
Armstrong
AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of
Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.
DOI:10.1001/jama.2020.4006.
[2]
Zhou
S, Yao Z. Roles of Infection in Psoriasis. INT J MOL SCI. 2022;23(13).
DOI:10.3390/ijms23136955.
[3]
Shah
H, Busquets AC. Psoriasis Flares in Patients With COVID-19 Infection or
Vaccination: A Case Series. Cureus. 2022;14(6):e25987.
DOI:10.7759/cureus.25987.
[4]
Zeng
H, Wang S, Chen L, et al. Biologics for Psoriasis During the COVID-19
Pandemic. Frontiers in medicine. 2021;8:759568.
DOI:10.3389/fmed.2021.759568.
[5]
Liu M,
Wang H, Liu L, et al. Risk of COVID-19 infection, hospitalization and
mortality in psoriasis patients treated with interleukin-17 inhibitors:
A systematic review and meta-analysis. FRONT IMMUNOL. 2022;13:1046352.
DOI:10.3389/fimmu.2022.1046352.
[6]
Lowes
MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. ANNU REV
IMMUNOL. 2014;32:227-255. DOI:10.1146/annurev-immunol-032713-120225.